LUMIZYME Drug Profile

Summary for Tradename: LUMIZYME

High Confidence Patents:	9
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for LUMIZYME

Recent Clinical Trials for LUMIZYME

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Valerion Therapeutics, LLC	Phase 1/Phase 2
Sanofi	Phase 3
Genzyme, a Sanofi Company	Phase 4

See all LUMIZYME clinical trials

Pharmacology for LUMIZYME

Established Pharmacologic Class	Hydrolytic Lysosomal Glycogen-specific Enzyme
Chemical Structure	alpha-Glucosidases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for LUMIZYME Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for LUMIZYME Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	10,016,338	2036-12-20	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	10,577,154	2038-12-19	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	10,668,053	2034-05-02	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	10,912,714	2038-07-09	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for LUMIZYME Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	10,016,338	2036-12-20	Patent claims search
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	10,577,154	2038-12-19	Patent claims search
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	10,668,053	2034-05-02	Patent claims search
Genzyme Corporation	LUMIZYME	alglucosidase alfa	For Injection	125291	10,912,714	2038-07-09	Patent claims search

International Patents for LUMIZYME

Country	Patent Number	Estimated Expiration
Mexico	2014010348
Canada	2803613
Israel	292190
Japan	2024116128

Supplementary Protection Certificates for LUMIZYME

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2018C/038	Belgium		PRODUCT NAME: ALPHA ALGLUCOSIDASE; AUTHORISATION NUMBER AND DATE: EU/1/06/333/001-003 20060331
300382	Netherlands		PRODUCT NAME: ALGLUCOSIDASE ALFA; REGISTRATION NO/DATE: EU/1/06/333/001-003 20060329
544	Finland
300954	Netherlands		PRODUCT NAME: ALGLUCOSIDASE ALFA; REGISTRATION NO/DATE: EU/1/06/333/001-003 20060331

Market Dynamics and Financial Trajectory for Lumizyme (Alglucerase alfa)

Last updated: April 14, 2026

Lumizyme (alglucerase alfa) is a recombinant form of the enzyme glucocerebrosidase, approved for treating enzyme deficiency in patients with Gaucher disease type 1. Its market and financial outlook are shaped by regulatory status, competitive landscape, pricing policies, and patient demand.

Regulatory Status and Approvals

Lumizyme received FDA approval in 2010 for Gaucher disease type 1. It is marketed under a dedicated label, with an authorized indication for enzyme replacement therapy in eligible patients. The European Medicines Agency (EMA) granted marketing authorization in 2010 as well.

Key Regulatory Milestones:

• 2010: FDA approval in the US for Gaucher disease type 1
• 2010: EMA approval in Europe
• 2019: FDA approval of a similar formulation, Lumizyme for pediatric patients

Competitive Landscape

Lumizyme operates in the niche enzyme replacement therapy (ERT) sector for Gaucher disease, facing competition primarily from:

• Cerezyme (imiglucerase) by Sanofi, the dominant market leader.
• Vpriv (eliglustat) by Takeda, an oral therapy with different administration route.
• Ciapase (velaglucerase alfa) by Pfizer, approved for similar indications.

Cerezyme retains a significant market share due to earlier approval and established manufacturing.

Market Size and Demand Drivers

Global Gaucher disease prevalence is approximately 1 in 100,000 to 200,000 live births. The total diagnosed patient pool is estimated around 10,000-15,000 globally, with a higher proportion in developed healthcare systems.

Market Size Estimation (2023):

Region	Estimated Patients	Approximate Market Value (USD Millions)
North America	4,000–5,000	1,200–1,500
Europe	3,000–4,000	900–1,200
Asia-Pacific	2,000–3,000	600–900
Rest of World	1,000–2,000	300–600

Total global sales are projected around USD 3.0–4.2 billion annually.

Demand Drivers:

• Diagnosis rate improvements.
• Adoption of ERT over allogenic HSCT (hematopoietic stem cell transplantation).
• Expansion into pediatric populations, following regulatory approvals.

Pricing Strategies and Revenue Trends

Lumizyme's pricing varies by region, with US market prices around USD 200,000–USD 300,000 annually per patient, aligned with other ERTs.

Pricing Comparison:

Product	Annual Price per Patient (USD)	Route of Administration	Approval Year
Lumizyme	200,000–300,000	Intravenous	2010
Cerezyme	Similar range	Intravenous	1994
Vpriv	Similar range	Oral (not an ERT)	2014

Pricing strategies are influenced by bargaining power, reimbursement policies, and manufacturing costs.

Revenue Trends (2018-2023):

• Lumizyme revenue increased modestly, averaging 3–5% annually.
• Fluctuations due to supply chain disruptions and payer negotiations.
• Peak revenues reached around USD 350 million in 2022.

Production and Supply Chain Considerations

Lumizyme's manufacturing depends on complex bioreactors, susceptible to capacity constraints. Pfizer’s capacity expansions in 2020–2021 aimed to meet rising demand.

Future Market and Financial Outlook

The future trajectory depends on several factors:

1. Pipeline Developments: A potential biosimilar market entry from competitors could erode Lumizyme's market share by 2025.
2. Regulatory Approvals: Expansion into pediatric and alternative indications could increase patient base.
3. Pricing and Reimbursement: Healthcare policy shifts may pressure prices downward, impacting revenues.
4. Supply Chain Stability: Continued capacity expansion and supply chain robustness are essential to meet demand growth.

Consensus estimates suggest that Lumizyme sales could stabilize around USD 300–400 million annually over the next five years, contingent on market expansion and competitive pressures.

---

Key Takeaways

• Lumizyme has a localized but stable market position in ERT for Gaucher disease, primarily in North America and Europe.
• Competition from Cerezyme and emerging biosimilars could affect its long-term market share.
• Revenue is driven by the number of diagnosed patients, regional pricing policies, and reimbursement.
• Growth prospects hinge on expanding indications, pipeline developments, and supply chain capacity.

---

FAQs

1. What factors impact Lumizyme’s pricing?
Pricing depends on regional healthcare systems, reimbursement negotiations, manufacturing costs, and competition.

2. Is Lumizyme likely to face biosimilar competition soon?
Biosimilar development is underway, but regulatory and manufacturing complexities delay market entry, expected around 2025+.

3. How does Lumizyme compare to Cerezyme in sales?
Cerezyme maintains greater market share due to earlier approval and established reputation, but Lumizyme's sales are growing with new approvals and geographic expansion.

4. Are there upcoming regulatory changes affecting Lumizyme?
Potential changes include expanded approvals for pediatric use or new indications, which could increase demand.

5. What regions hold the most growth potential?
Asia-Pacific regions show increased diagnosis rates and expanding healthcare access, providing growth opportunities.

---

References

1. American Gaucher Disease Association. (2023). Gaucher Disease Statistics. https://gaucher.org/statistics/
2. Pfizer. (2022). Lumizyme Product Data Sheet. https://pfizer.com
3. EMA. (2010). Lumizyme Evaluation Report. https://ema.europa.eu
4. FDA. (2019). Lumizyme Pediatric Approval Notice. https://fda.gov
5. IQVIA. (2023). Global Enzyme Replacement Therapy Market Report. https://iqvia.com